{"slideshow_credits": null, "snippet": "The Pharmaceutical Research and Manufacturers of America discusses the regulatory barriers to getting product modifications to market.", "abstract": null, "section_name": "Opinion", "print_page": null, "document_type": "article", "byline": [], "web_url": "http://www.nytimes.com/2016/03/12/opinion/cancer-drug-dosing.html", "lead_paragraph": "The Pharmaceutical Research and Manufacturers of America discusses the regulatory barriers to getting product modifications to market.", "headline": {"print_headline": "Cancer Drug Dosing", "main": "Cancer Drug Dosing", "content_kicker": "Letter", "kicker": "Letter"}, "_id": "56e3375438f0d81b768a681b", "word_count": "156", "multimedia": [], "pub_date": "2016-03-12T00:00:00Z", "source": "The New York Times", "news_desk": "Letters", "keywords": [{"name": "subject", "value": "Drugs (Pharmaceuticals)", "is_major": "N", "rank": "1"}, {"name": "subject", "value": "Cancer", "is_major": "N", "rank": "2"}], "blog": [], "subsection_name": null, "type_of_material": "Letter"}